Information Provided By:
News For MD From the Last 2 Days
MD
Feb 24, 2020 | 09:08 EST
JPMorgan analyst Gary Taylor lowered the firm's price target on Mednax to $20 from $33 and keeps a Neutral rating on the shares. To calls the company's situation "fluid seems an understatement, but the preponderance of surprise continues to be to the downside," Taylor tells investors in a post-earnings research note.